People in France who have received a first dose of the COVID-19 vaccine from AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) may be offered an alternative vaccine for their second shot, Reuters news agency reported on Friday.
Health Minister Olivier Veran told RTL radio that he expected the French national health authority, Haute Autorité de santé (HAS), to recommend that recipients of a first dose of AstraZeneca's traditional COVID-19 vaccine who are under the age of 55 should get a second shot with a messenger-RNA (mRNA) vaccine.
Two mRNA vaccines, one made by Pfizer (NYSE:PFE) and its German partner BioNTech and another from Moderna Inc (Nasdaq:MRNA), are approved for use in France.
There are some concerns about a potentially higher risk of rare blood clots among younger people who have had the AstraZeneca vaccine.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne